Back

Twelve-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Diabetes and heart disease Metabolic Syndrome, Insulin, Insulin Resistance ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Konstantinos Katogiannis

Attikon University Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Regional distribution of diffuse fibrosis in the basal and mid-ventricular AHA segments in patients with type 2 diabetes
Doctor A. Bojer (Gentofte, DK)
Abstract Slides Video
Presentation thumbnail
Circadian heart rate fluctuations predict 21-year cardiovascular and all-cause mortality in type 2 and type 1 diabetes
Doctor L. Nesti (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
The epicardial adipose tissue volume is in patients with type 2 diabetes mellitus associated with a lowered myocardial perfusion reserve
Doctor A. Johansen (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Impact of diabetes on vascular endothelial growth factor D and cardiovascular mortality in patients with suspected or known coronary artery disease: the ANOX study
Doctor H. Wada (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Type 2 diabetes individuals have a shorter QRS duration, prolonged QTc interval, flatter T wave, and reduced left ventricular cycle volumes compared to matched controls in the UK Biobank
Ms A. Bertrand (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and heart disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report
thumbnail
Congress Presentation
Effects of SGLT-2i and GLP-1RA in vascular function parameters: the impact of the weight loss
thumbnail
Congress Presentation
Empagliflozin significantly reduces the capacity of sera to induce endothelial dysfunction in Ischemia Non-Obstructive Coronary Arteries (INOCA): EMbArk phase II pilot trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources